Phaseline

Companies › Elixirgen Therapeutics

Elixirgen Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EXG34217
Ex vivo-expanded hematopoietic stem cell therapy
–Phase 1Telomere ShorteningOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04211714EXG34217Phase 1Telomere ShorteningHematologyOct 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.